Rivian Automotive, Inc. vs SELLAS Life Sciences Group Inc. Common Stock — how do they compare? Rivian Automotive, Inc. trades at $14.03 (market cap $20.75B), while SELLAS Life Sciences Group Inc. Common Stock trades at $11.7 (market cap $2.27B). The key difference: Rivian Automotive, Inc. is far larger — about 9.1× SELLAS Life Sciences Group Inc. Common Stock's market cap, and SELLAS Life Sciences Group Inc. Common Stock is trading nearer its 52-week high, Rivian Automotive, Inc. nearer its low. Which is the better fit depends on your goals.
| RIVN | SLS | |
|---|---|---|
Market Cap | $20.75B | $2.27B |
Volume | 26,144,654 | 4,179,659 |
Sector | Consumer Cyclical | Health |
52-Week High | $22.45 | $15.46 |
52-Week Low | $12.50 | $1.39 |
Typical Hold Time | 61 Days | — |
Enterprise Value | $20.79B | $2.14B |
Signals from Pluang's Aura AI — not financial advice
Rivian Automotive (RIVN) trades at $14.03, down 2.16% amid bearish technical signals despite beating Q3 2026 delivery estimates with 19,248 vehicles. The company maintains negative profitability with a -54.95% net income margin but shows improving revenue trends and cash flow reduction. Analyst consensus remains cautiously optimistic with a $16.89 price target, though technical indicators show selling pressure with RSI near oversold levels.
Rivian presents a high-risk growth opportunity with significant operational improvements but persistent losses. The R2 SUV rollout and autonomy technology development offer long-term potential, while near-term challenges include cash burn and competitive EV market pressures. Investors should weigh improving fundamentals against substantial execution risks in a capital-intensive industry.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Rivian Automotive, Inc. is an automotive technology company. The Company designs and manufactures vans, trucks, and sports utility vehicles, as well as offers repair and maintenance services. Rivian Automotive serves customers in North America and the United Kingdom.
Read more on RIVN →SELLAS Life Sciences is a late-stage clinical biopharmaceutical company developing therapies for cancer. Its programs include a WT1-targeting cancer immunotherapy and a selective CDK9 inhibitor.
Read more on SLS →